1198408-35-3

Basic information

• Product Name: tert-butyl 4-(6-aMinopyridin-3-yl)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-(6-aMinopyridin-3-yl)piperidine-1-carboxylate;tert-Butyl 4-(6-aminopyridin-3-yl)
• CAS NO: 1198408-35-3
• Molecular Formula: C₁₅H₂₃N₃O₂
• Molecular Weight: 277.36202
• Mol File: 1198408-35-3.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 422.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.134±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 6.80±0.26(Predicted)
• CAS DataBase Reference: tert-butyl 4-(6-aMinopyridin-3-yl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(6-aMinopyridin-3-yl)piperidine-1-carboxylate(1198408-35-3)
• EPA Substance Registry System: tert-butyl 4-(6-aMinopyridin-3-yl)piperidine-1-carboxylate(1198408-35-3)

Safety Data

• Hazardous Substances Data: 1198408-35-3(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-(6-aminopyridin-3-yl)piperidine-1-carboxylate is a synthetic chemical compound. It contains a tertiary butyl group and a piperidine ring, which is joined to a six-membered pyridine ring with an amino functional group at the 6-position. The carbonyl group of the piperidine ring is attached to an ester functional group, which in this case is a tert-butyl ester. This molecule is important because it can serve as a building block in synthetic organic chemistry, particularly in the creation of pharmaceuticals and other bioactive molecules. As this is a specialized chemical, it may seem to be important for lab research rather than any direct application.

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 633283-53-1 1-N-(tert-butoxycarbonyl)-4-N-(6-chloropyridin-3-yl)piperazine 
• 228710-82-5 5-bromo-2-(2,5-dimethyl-pyrrol-1-yl)-pyridine 
• 41780-52-3 N’-(1-benzylpiperidin-4-ylidene)-4-methylbenzenesulfonohydrazide 
• 182344-63-4 N-(5-bromo-pyridin-2-yl)-2,2-dimethyl-propionamide 
• 741683-17-0 4-(6-fluoro-3-pyridyl)-N-tert-butoxycarbonylpiperidine 
• 741683-15-8 4-(6-fluoro-3-pyridyl)-4-hydroxy-N-tert-butoxycarbonylpiperidine 
• 766-11-0 5-bromo-2-fluoropyridine 

Downstream Products

• 1198408-37-5 C₂₄H₂₇ClN₄O₃ 
• 1360055-29-3 6-tert-Butyl-8-fluoro-2-{2-hydroxymethyl-3-[5-(1'-isopropyl-1',2',3',4',5',6'-hexahydro-[3,4']bipyridinyl-6-ylamino)-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl]-phenyl}-2H-phthalazin-1-one 
• 1360055-30-6 6-tert-Butyl-2-{3-[5-(1'-ethyl-1',2',3',4',5',6'-hexahydro-[3,4]bipyridinyl-6-ylamino)-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl]-2-hydroxymethyl-phenyl}-8-fluoro-2H-phthalazin-1-one 
• 1360055-67-9 6-tert-Butyl-8-fluoro-2-{2-hydroxymethyl-3-[1-methyl-5-(1'-methyl-1',2',3',4',5',6'-hexahydro-[3,4]bipyridinyl-6-ylamino)-6-oxo-1,6-dihydro-pyridazin-3-yl]-phenyl}-2H-phthalazin-1-one 
• 1360056-63-8 2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-6-(5-(5-(1-isopropylpiperidin-4-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)benzyl acetate 
• 1360056-65-0 2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-6-(5-(5-(1-ethylpiperidin-4-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)benzyl acetate 
• 1360057-17-5 2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-6-(1-methyl-5-(5-(1-methylpiperidin-4-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridazin-3-yl)benzyl acetate 
• 1360057-06-2 C₄₁H₄₆FN₇O₆ 

Relevant articles and documents

INHIBITORS OF TRPC6

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF

The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.

PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.